Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement

Pier Mannuccio Mannucci, Maria Elisa Mancuso, Elena Santagostino, Massimo Franchini

Research output: Contribution to journalArticlepeer-review


In recent years, advances in the pharmacological treatment of hemophilias A and B have mainly focused on the development of long-acting factor (F)VIII and FIX products. Alternative approaches not based on the replacement of the missing factor have also been explored, with the aim of producing therapeutic agents with reduced immunogenicity and yet equally effective in patients with or without inhibitors. These new classes of hemostatic agents act mainly by bypassing the need of FVIII and FIX in tenase formation, quenching anticoagulant pathways, enhancing the activity of some coagulation factors or stabilizing the fibrin clot. Current knowledge on the status of development of these novel molecules is summarized in this narrative review. We also surmise that the main interests for these products not based on the replacement of FVIII or FIX in deficient patients pertain to the potential for bleeding prevention in inhibitor patients, an earlier and easier prophylaxis implementation thanks to subcutaneous administration and prolonged half-life, and a low immunogenicity with the potential for prevention of inhibitor development in high-risk patients.

Original languageEnglish
Pages (from-to)526-532
Number of pages7
JournalSeminars in Thrombosis and Hemostasis
Issue number5
Publication statusPublished - 2016


  • ACE910
  • antithrombin
  • concizumab
  • FV variant
  • FX variant
  • hemostatic agents

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement'. Together they form a unique fingerprint.

Cite this